Brown fat dissipates energy as heat and protects against obesity. Here, we identified nuclear factor I-A (NFIA) as a transcriptional regulator of brown fat by a genome-wide open chromatin analysis of murine brown and white fat followed by motif analysis of brown-fat-specific open chromatin regions. NFIA and the master transcriptional regulator of adipogenesis, PPARγ, co-localize at the brown-fat-specific enhancers. Moreover, the binding of NFIA precedes and facilitates the binding of PPARγ, leading to increased chromatin accessibility and active transcription. Introduction of NFIA into myoblasts results in brown adipocyte differentiation. Conversely, the brown fat of NFIA-knockout mice displays impaired expression of the brown-fat-specific genes and reciprocal elevation of muscle genes. Finally, expression of NFIA and the brown-fat-specific genes is positively correlated in human brown fat. These results indicate that NFIA activates the cell-type-specific enhancers and facilitates the binding of PPARγ to control the brown fat gene program.
Obesity and its complications including diabetes amount to a worldwide epidemic. While white adipose tissue (WAT) stores energy as lipids and expands in obesity, brown adipose tissue (BAT) is specialized to dissipate energy through the uncoupling protein-1 (UCP1) on the mitochondrial inner membrane. When activated, UCP1 dissipates the electrochemical gradient that is normally used for adenosine triphosphate (ATP) synthesis, resulting in energy expenditure in the form of heat 1 . Although the existence of human BAT was controversial until recently, since the re-discovery of BAT in human adults [2] [3] [4] [5] [6] , it has been considered a potential target in the treatment of obesity. Human BAT activity is inversely correlated with body mass index 3 , and studies have shown that chronic cold exposure 7, 8 and β3 adrenergic receptor agonist administration 9 successfully recruit human BAT and increase systemic energy expenditure.
Lineage tracing has demonstrated that brown fat and skeletal muscle share a common progenitor, but brown fat and white fat do not 10 . Both brown fat and skeletal muscle derive from a Myf5-positive precursor, and a transcriptional cofactor PRD1-BF1-RIZ1 homologous domain containing 16 (PRDM16) works as a cell-fate switch [10] [11] [12] .
The master transcriptional regulator of adipogenesis-peroxisome proliferator-activated receptor γ (PPARγ)-and its agonist were also shown to activate the brown fat gene program 13, 14 . Motif analysis of PPARγ-binding sites in BAT identified early B cell factor 2 (EBF2) as a transcriptional regulator of brown fat 15 . However, much remains elusive in the genome-wide landscape of brown fat development.
To gain insight into the underlying mechanism of brown fat development in a global and unbiased manner, we performed formaldehyde-assisted isolation of regulatory elements (FAIRE) * * Motifs enriched in BAT-specific FAIRE peaks and eWAT-or iWAT-specific FAIRE peaks. The motif analysis was performed once on the basis of the FAIRE-seq data set. (d) mRNA expression levels of the NFI family in C2C12 myoblasts, immortalized brown adipocytes and 3T3-L1 white adipocytes before (pre) and after (diff) differentiation (mean ± s.e.m.; n = 3 independent samples). (e) mRNA expression levels of the NFI family in soleus muscle, quadriceps muscle, BAT, iWAT and eWAT (mean ± s.e.m.; n = 7 independent samples; * P < 0.05, * * P < 0.01). (f) Western blot analysis of NFIA in representative samples from soleus muscle, quadriceps muscle, BAT, iWAT and eWAT. β-actin was used as a loading control. Representative images of two independent experiments are shown. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
coupled with high-throughput sequencing 16 on murine BAT and WAT to profile the tissue-specific accessible chromatin regions. Through motif analysis of BAT-specific open chromatin regions, we identified NFIA as a transcriptional regulator of brown fat. NFIA exerts its effects by co-localizing with PPARγ at cell-type-specific enhancers.
RESULTS
The NFI motif within BAT open chromatin BAT and WAT share a common transcriptional program regulated by PPARγ and CCAAT/enhancer binding proteins (C/EBPs). However, these tissues also have depot-selective gene programs that are responsible for their specific functions 11, 15, 17 . Regulatory elements controlling gene expression are characterized by open chromatin structures accessible to transcription factors and cofactors. We performed FAIRE-seq analyses of murine interscapular BAT, inguinal WAT (iWAT) and epididymal WAT (eWAT) to map open chromatin regions genome-wide, and we identified 24,322 FAIRE peaks for BAT, 10,012 for iWAT and 12,656 for eWAT (Fig. 1a,b) . Genes near BAT-specific FAIRE peaks were associated with gene ontology (GO) terms such as brown fat cell differentiation ( Supplementary  Fig. 1a,b) , suggesting that the FAIRE-seq experiments unbiasedly identified functionally active, depot-specific accessible chromatin regions. Through motif analysis, in addition to known regulators such as C/EBPβ, EBF2 and PPARγ (refs 13,15,18) , we found that the binding motif for the NFI transcription factor was the most highly enriched within BAT-specific open chromatin regions (Fig. 1c) . (c-e) Myogenic genes (c), common adipocyte genes (d) and brown-fatspecific genes (e) were quantified by RT-qPCR at the indicated times (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01). fsk, forskolin. (f) Oxygen consumption of control and NFIA-expressing C2C12 myoblasts (mean ± s.e.m.; n = 10 independent samples; * * P < 0.01).
(g) Control shRNA or shRNA for NFIA was introduced into immortalized brown adipocytes and the cells were stained with Oil Red O six days after inducing adipocyte differentiation. Scale bar, 50 µm. (h-j) Nfia (h), Pparg and Fabp4 (i), Ppargc1a and Ucp1 (j) were quantified by RT-qPCR at the indicated times (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01; NS, not significant.). (k) Western blot analysis of NFIA, UCP1 and PPARγ in the indicated cells. β-actin was used as a loading control. Representative images of two independent experiments are shown. Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
Of the four isoforms of the NFI family 19 , we found that Nfia was highly expressed in brown adipocytes compared with its expression in 3T3-L1 white adipocytes or C2C12 myoblasts. Moreover, the gene expression level of Nfia was robustly induced during brown adipocyte differentiation (Fig. 1d) . NFIA was also highly expressed in BAT compared with WAT or skeletal muscle at both the RNA and protein levels (Fig. 1e,f) . Furthermore, the expression level of Nfia was increased when mice are challenged by exposure to cold or β3-agonist CL316,243
( Supplementary Fig. 1c-e) . These findings indicate that NFIA is a candidate transcriptional regulator that defines brown adipocyte identity.
NFIA induces brown adipogenesis
To examine whether NFIA can induce adipocyte differentiation from myoblasts, we introduced NFIA into C2C12 myoblast cell lines using retroviral vectors (Fig. 2a) . The cells were grown to confluence and treated with an adipogenic cocktail. Strikingly, NFIA-expressing cells differentiated into lipid-filled adipocytes (Fig. 2b) . Consistent with cell morphology, NFIA induced expression of the master regulator Pparg and the general adipocyte marker Fabp4 (Fig. 2d ). In contrast, myogenic genes such as Myod1 and Myog were suppressed by NFIA (Fig. 2c) . NFIA also induced brown-fat-specific genes including Cidea and Ppargc1a as well as the thermogenic gene Ucp1 in response to elevated cyclic AMP through forskolin treatment (Fig. 2e) . Functionally, NFIA-expressing cells showed induced uncoupled respiration (Fig. 2f) .
Hierarchical clustering of genes quantified by RNA-seq showed the global changes in gene expression caused by the introduction of NFIA (Supplementary Fig. 2a) . When we defined genes selective for BAT and skeletal muscle (SKM) by fold changes of expression levels between these tissues, BAT-selective genes were enriched in the cluster of genes upregulated by NFIA (P = 9.9 × 10 −28 , chi-square test), while SKMselective genes were enriched in the cluster of genes downregulated by NFIA (P = 2.3 × 10 −32 ). And GO analysis independently supported this observation ( Supplementary Fig. 2b ). Taken together, these data indicate that introduction of NFIA into myoblasts drives brown adipocyte differentiation while inhibiting myogenic differentiation.
We also tried introduction of NFIA into 3T3-F442A white preadipocyte cells ( Supplementary Fig. 2d ). The effect of NFIA on lipid accumulation and on common adipocyte gene expression after differentiation was modest ( Supplementary Fig. 2c ,e). However, NFIA very strongly increased the expression levels of the brown-fat-specific genes ( Supplementary Fig. 2f ), suggesting that NFIA can drive the brown fat gene program also in white preadipocytes.
To test the endogenous role of NFIA, we next performed lossof-function experiments. We introduced a short hairpin (sh) RNA for NFIA into brown adipocytes and achieved significant knockdown throughout the differentiation (Fig. 2h,k) . While the effects of NFIA knockdown on cell morphology and on common adipocyte gene expression were not significant (Fig. 2g,i) , expression levels of the brown-fat-specific genes such as Ppargc1a and Ucp1 were significantly reduced (Fig. 2j) . Expression of UCP1 protein was also highly reduced ( Fig. 2k) . Similarly, when we introduced a small interfering (si) RNA for NFIA by electroporation into fully differentiated brown adipocytes, expression levels of the brown-fat-specific genes were significantly reduced ( Supplementary Fig. 2g-j) . These results suggest that NFIA is required for both activation and maintenance of the brown-fatspecific gene expression. Altogether, our gain-and loss-of-function experiments show that NFIA is capable of and required for controlling the brown fat gene program.
NFIA and PRDM16 work in parallel with each other
The effect of NFIA on the brown fat gene program prompted us to examine the relationship with and requirement for PRDM16, which perform a similar function in this context. Although massspectrometric analysis suggested that NFIA is included in the PRDM16 protein complex 18 , our co-immunoprecipitation experiments showed that NFIA does not bind physically to PRDM16 (Fig. 3a) . Introduction of NFIA into myoblasts did not induce Prdm16 expression. However, introduction of PRDM16 did induce Nfia expression while introduction of PPARγ did not (Fig. 3b,c) . Importantly, PRDM16 was dispensable for the effect of NFIA, because NFIA was capable of stimulating adipocyte differentiation and stimulating the brown-fat-specific gene expression even when PRDM16 was knocked down (Fig. 3d-g ). Interestingly, the opposite was also true ( Fig. 3h-k) . Overall, these results suggest that NFIA and PRDM16 work in parallel with each other.
NFIA binds to the brown fat enhancers
To dissect the genome-wide binding landscape of NFIA in brown adipocyte differentiation, we performed chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) analysis using the NFI antibody, which reacts primarily with NFIA, but also with NFIC and NFIX. We also performed ChIP-seq for PPARγ, C/EBPα, C/EBPβ, EBF2 and H3K27 acetylation (H3K27Ac). We additionally performed assays for transposase-accessible chromatin coupled with high-throughput sequencing (ATAC-seq) for accessible chromatin regions 20 . We further performed ChIP-seq for NFIA with the FLAG M2 antibody in C2C12 myoblasts that expressed FLAGtagged NFIA. We identified 12,486 and 12,748 NFI-binding sites, respectively, on day 0 and day 6 of differentiation and the majority of NFI-binding sites were located distal to genes, as is the case with PPARγ ( Fig. 4a and Supplementary Fig. 3a ). Motif analysis showed that NFI-binding sites in brown adipocytes and NFIA-binding sites in NFIA-expressing C2C12 myoblasts were strongly enriched with NFI motif (Fig. 4b and Supplementary Fig. 3b ,c), in agreement with direct DNA binding. We observed that NFI binds to the enhancers of the master regulator Pparg and the brown-fat-specific genes such as Cidea and Ucp1 (Fig. 4c) . Importantly, most of the NFI-binding sites in brown adipocytes and NFIA-binding sites in NFIA-expressing C2C12 myoblasts overlapped each other at BAT FAIRE peaks (Supplementary Fig. 3e ). Furthermore, when we defined BAT-and WATselective genes by fold changes of expression levels between these tissues, BAT-selective genes were closer to NFI-binding sites than were WAT-selective genes (Fig. 4d) , and BAT-selective genes harboured more NFI-binding sites than did WAT-selective genes or all genes within ±50 kilobases (kb) of the transcription start site (TSS). (Fig. 4e) . And the NFI binding signal was highly enriched near BAT-selective genes compared with that signal near WAT-selective genes or all genes (Fig. 4f) . These results indicate that NFI binding is enriched at brownfat-specific enhancers.
Co-localization of NFIA and PPARγ
We also found that the binding sites of NFI and PPARγ often overlapped each other. Since co-localization of transcription factors at the chromatin is crucial for both cell-fate decision 21 and cell-typespecific signalling 22 , we investigated co-localization of NFI and PPARγ genome-wide. We found that the binding sites of NFI overlapped those of PPARγ at 63% of all binding sites in differentiated brown adipocytes (8,001 of 12,748 sites, Fig. 5a ). Most strikingly, the majority of the co-localizing peaks were pre-occupied by NFI but not occupied by PPARγ, C/EBPα, C/EBPβ nor EBF2 before differentiation, and these sites exhibited a high level of H3K27 acetylation and chromatin accessibility, markers of active enhancers even before differentiation (Fig. 5b,c) . And the binding sites of NFI were substantially concordant between day 0 and day 6 of differentiation, unlike other transcription factors examined ( Supplementary Fig. 3f-j) .
To test whether the co-localization of NFI and PPARγ is associated with gene expression, we counted the number of co-localizing sites per gene within ±50 kb regions around the BAT-and WAT-selective and/or 3×FLAG-tagged PPARγ followed by western blot analysis to detect 3×FLAG-tagged PPARγ, as a positive control 10 . Right, immunoprecipitation of V5-tagged PRDM16 from HEK293 cells expressing V5-tagged PRDM16 and/or NFIA followed by western blot analysis to detect NFIA. Representative images of two independent experiments are shown. (b) RT-qPCR analysis of Prdm16 in control or NFIA-expressing C2C12 cells during the induction of adipocyte differentiation (mean ± s.e.m.; n = 3 independent samples; NS, not significant). (c) RT-qPCR analysis of Nfia in control, PPARγ-or PRDM16-expressing C2C12 cells (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01). (d) Control shRNA or shRNA for PRDM16 was introduced into control or NFIA-expressing C2C12 myoblasts, and the cells were stained with Oil Red O seven days after inducing adipocyte differentiation. Scale bar, 50 µm. (e-g) Prdm16 and Nfia (e), the general adipocyte marker Fabp4 (f) and the brown-fat-specific genes (g) were quantified by RT-qPCR at the indicated times (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01; NS, not significant). (h) Control shRNA or shRNA for NFIA was introduced into control or PRDM16-expressing C2C12 myoblasts, and the cells were stained with Oil Red O seven days after inducing adipocyte differentiation. Scale bar, 50 µm. (i-k) Nfia and Prdm16 (i), the general adipocyte marker Fabp4 (j) and the brown-fat-specific genes (k) were quantified by RT-qPCR at the indicated times (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01; NS, not significant). Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
genes stratified by the fold change of expression. The results showed that the more the genes were expressed in brown fat compared with expression in white fat, the higher the number of co-localizing sites per gene (Fig. 5d) . We observed that the co-localization was enriched near BAT-selective genes also in white adipocytes ( Supplementary  Fig. 3k,l) . NFI-binding sites near BAT-selective genes were closer to DR-1 motifs (the consensus motif for PPARγ) compared with those near WAT-selective genes ( Supplementary Fig. 3m) , suggesting that the co-localization near BAT-selective genes is, at least in part, determined by the DNA sequence itself.
To reveal the functional consequences of NFIA and PPARγ co-localization, we utilized a model system in which we introduced ,258) , BAT-and WAT-selective genes (n = 549 and n = 849, respectively). The box shows the median, and the first and third quartiles. The whisker shows the value still within one-and-a-half times the interquartile range. The genome-wide analyses were performed once on the basis of the ChIP-seq data set.
into C2C12 myoblasts either PPARγ alone or both PPARγ and NFIA. As previously reported, introduction of PPARγ alone is sufficient to promote adipocyte differentiation 10 . Co-expression of NFIA with PPARγ did not alter the degree of differentiation-as judged by both Oil Red O staining and general adipocyte marker Fabp4 expression (Fig. 6a,b) . We confirmed that NFIA binds to the brown-fat-specific enhancers in this model system (Fig. 6d) . Note especially that the binding of PPARγ to those enhancers near Cidea, Ppara, Ppargc1a and Ucp1 was significantly facilitated when NFIA co-localized with PPARγ ( Fig. 6e) , even though PPARγ protein levels were similar in both cells (Fig. 6c) . We observed that the binding of PPARγ to some of those enhancers was already facilitated before differentiation ( Supplementary Fig. 4a,b) . Conversely, the binding of NFIA to those enhancers was independent of the co-localization of PPARγ, since NFIA in cells without PPARγ was able to bind to these loci as strongly as NFIA in cells with PPARγ ( Supplementary Fig. 4c,d and Fig. 6d) . Moreover, chromatin accessibility of those enhancers was dramatically increased when NFIA and PPARγ were co-localized (Fig. 6f) . Finally, the co-localization robustly activated transcription of those genes (Fig. 6g) . Together, these results demonstrate that co-localization of NFIA facilitates PPARγ binding to the brown-fat-specific enhancers for controlling the brown-fat-specific gene expression.
Role of NFIA in BAT in vivo
To evaluate the physiological relevance of NFIA in BAT in vivo, we analysed BAT in NFIA-knockout (KO) mice. NFIA-KO mice are born in Mendelian ratios but die within a week of birth due to neurological deficits including agenesis of corpus callosum and hydrocephalus 23 . We therefore analysed the BAT of neonates soon after birth. BAT masses and morphology were comparable among three genotypes (Fig. 7a) . However, we observed significantly decreased expression of Ucp1 messenger RNA (Fig. 7b ) and UCP1 protein (Fig. 7c) in NFIA-KO tissues. By ChIP-qPCR analysis of those tissues, we also observed severely impaired PPARγ binding to the Ucp1 −4.5 kb enhancer (Fig. 7d) . Notably, we observed co-localization of NFIA and PPARγ at the Ucp1 −4.5 kb enhancer in our model system (Fig. 6d,e) and expression levels of Pparg were comparable between wild-type (WT) and NFIA-KO tissues (Supplementary Fig. 5a ). Consistently, the binding of PPARγ to the Ucp1 −4.5 kb and Ucp1 −11.7 kb enhancer was highly decreased when NFIA was knocked down in brown adipocytes ( Supplementary Fig. 5b ). These results suggest that colocalization of NFIA and PPARγ is necessary for optimal expression of the Ucp1 gene in vivo.
To evaluate genome-wide changes in gene expression by NFIA-KO, we performed RNA-seq analysis (Fig. 7e) . The expression levels of a battery of brown-fat-specific genes and mitochondrial genes were significantly decreased, while common fat genes were relatively maintained. In contrast, muscle-specific genes were reciprocally elevated by NFIA-KO ( Supplementary Fig. 5c-f) . Genes downregulated by NFIA-KO were associated with GO terms such as triglyceride biosynthetic process and brown fat differentiation, and genes upregulated by NFIA-KO were associated with GO terms such as skeletal myofibril assembly (Fig. 7f) . A scatter plot of gene expression changes that were due to introduction of NFIA into myoblasts and NFIA-KO in BAT (Fig. 7g ) demonstrated that BATselective genes (p = 5.1 × 10 −29 , chi-square test) and SKM-selective genes (p = 1.7 × 10 −14 ) are reciprocally regulated by both gain-and loss-of-function studies. Finally, in db/db mice-a mouse model of obesity and diabetes-we found that expression levels of both Nfia and Ucp1 in BAT were suppressed compared with levels in C57BL6/J mice ( Supplementary Fig. 5g ), suggesting that downregulation of NFIA may play a pathophysiological role in the development of obesity and diabetes. Together, these results demonstrate that NFIA is required for the optimal activation of the brown fat gene program and repression of the muscle gene program in vivo.
NFIA in human brown fat
To explore the possible role of NFIA in human BAT, we analysed the perirenal BAT of human patients with pheochromocytoma and with non-functional adrenal tumours. Human perirenal BAT is considered relatively close to murine classical BAT in terms of developmental origin and gene signature 24 . Perirenal BAT is activated in patients with pheochromocytoma, and the gene expression pattern is similar to that of classical BAT in mice 25 . We observed that NFIA expression −97 kb and Ucp1 9.5 kb are background sites. The representative result of three independent experiments is shown (n = 2 independent samples; mean ± s.e.m.). (e) ChIP-qPCR analysis of PPARγ. Cidea 29 kb, Ppara 21 kb, Ppargc1a −97 kb and Ucp1 9.5 kb are background sites. The representative result of three independent experiments is shown (n = 2 independent samples; mean ± s.e.m.). Source data for d,e are provided in Supplementary Table 2 . (f) FAIRE-qPCR analysis. Cidea 29 kb, Ppara 21 kb, Ppargc1a −97 kb and Ucp1 9.5 kb are background sites (mean ± s.e.m.; n = 3 independent samples; * * P < 0.01). (g) RT-qPCR analysis of the indicated genes (mean ± s.e.m.; n = 3 independent samples; * P < 0.05, * * P < 0.01). Unprocessed original scans of blots are shown in Supplementary Fig. 8 .
was higher in patients with pheochromocytoma compared with those who had non-functional adrenal tumours (Fig. 8a) . Furthermore, expression levels of the brown-fat-specific genes including UCP1 and PPARGC1A were positively and significantly correlated with NFIA expression (Fig. 8b) . We also analysed human brown and white adipocytes, obtained from supraclavicular and subcutaneous regions, respectively 26 . Expression levels of NFIA were higher in human brown adipocytes compared with white adipocytes throughout the differentiation (Fig. 8c) . Finally, we measured the expression levels of NFIA in BAT and WAT of human necks 27 . The expression of NFIA was numerically higher in BAT than expression in WAT, although the difference did not reach statistical significance, possibly due to limited sample size (Fig. 8d) . These results indicate that NFIA may also control the brown fat gene program in humans.
DISCUSSION
PPARγ is the master transcriptional regulator of adipocyte differentiation 28 . Here, we show that NFIA co-localizes with PPARγ at the brown-fat-specific enhancers to control the brown fat gene program. The binding of NFIA precedes and facilitates the binding of PPARγ. NFIA may recruit chromatin remodelling complexes such as Swi/Snf, as reported in the case of human adrenal cells 29 . Alternatively, NFIA may work as a pioneer factor 30 by facilitating structural changes of chromatin that increase accessibility and by recruiting PPARγ. Consistently, knockdown of PPARγ results in almost complete loss of the effect of NFIA ( Supplementary Fig. 6a-d) .
In support of this, genetic variations that alter NF-1 motifs were reported to affect not only the binding of NFI, but also the binding of PPARγ (ref. 31) , chromatin accessibility 32 and the enhancer activity 33 . Proximally co-occupied transcription factors often compete with a nucleosome to access DNA 34 , and co-localization of NFIA and PPARγ is more likely to result in nucleosome displacement than binding of NFIA or PPARγ alone, probably leading to increased chromatin accessibility, enhancer activity and gene expression. Nevertheless, (a) Expression levels of NFIA in perirenal brown fat of human patients with pheochromocytoma or non-functional adrenal tumours (mean ± s.e.m.; n = 7 independent samples for non-functional adrenal tumours and n = 11 independent samples for pheochromocytoma; * * P < 0.01). (b) Correlation of expression of the brown-fat-specific genes and NFIA expression.
(c) Expression levels of NFIA in human brown (supraclavicular) and white (abdominal subcutaneous) adipocytes before and after differentiation (mean ± s.e.m.; n = 5 independent samples for white adipocytes and n = 6 independent samples for brown adipocytes; * * P < 0.01). (d) RT-qPCR analysis of NFIA in human neck WAT (subcutaneous) and BAT (carotid sheath) (n = 5 independent samples). The analyses were performed once because human samples were highly limited.
further studies are needed to clarify the whole picture of chromatin remodelling during brown fat development caused by NFIA and other factors. Although NFIA and PRDM16 perform a similar function in brown adipocyte differentiation, we show that these two factors work in parallel with each other. And both NFIA and PRDM16 are indispensable for the full activation of the brown fat gene program. Indeed, expression levels of Prdm16 were relatively unaffected in NFIA-KO mice ( Supplementary Fig. 5c ), and the opposite was also the case 35 (fold change of Nfia expression in KO/WT was 0.99). Additionally, PGC1α is also dispensable for the effect of NFIA, because the effect of NFIA is totally maintained even when PGC1α is knocked down (Supplementary Fig. 6e-h ). Although expression levels of Adrb3 were severely reduced by NFIA-KO, Adrb3 was also dispensable for the effect of NFIA ( Supplementary Fig. 6i-l) .
The BAT of NFIA-KO mice showed impaired expression of the brown fat gene program. However, the appearance and mass of the BAT was relatively preserved, suggesting that co-localization of NFIA and PPARγ alone may not be sufficient for determining brown fat cell fate. Cell-fate determination may be achieved through the contribution of multiple factors, and deficiency of NFIA alone could be compensated for. The investigation at the prenatal stage 36 and lineage tracing experiments 10 will help characterize the role of NFIA more definitively. Additionally, tissue-specific deletion of NFIA in mice will be required for investigating the role of NFIA in adult BAT in systemic metabolism.
Since brown fat and skeletal muscle share a common progenitor, repressing the muscle gene program is required in addition to inducing the brown fat gene program to direct the cell-fate determination toward brown fat. However, many of the myogenic genes do not have NFIA-binding sites at their enhancers, and the repressive effect of NFIA on muscle genes may be indirect. Note that PPARγ is reported to suppress MyoD-a master regulator of myogenesis-through enhanced ubiquitylation and degradation of the MyoD protein 37 . NFIA may suppress myogenesis by inducing PPARγ; uncharacterized, PPARγ-independent mechanisms may also be involved.
Originally, NFI was found to bind to an enhancer of the Fabp4 gene 38 , and we previously reported that the NF-1 motif is enriched within open chromatin regions of differentiated white adipocytes compared with undifferentiated cells 39 . In this study, we found that the NF-1 motif is enriched in BAT-specific-not WAT-specificopen chromatin regions in vivo. NFIA is important for general adipogenesis-probably by inducing PPARγ-and NFIA is more important for the BAT-selective gene program than the WAT-selective gene program. Indeed, the overlap of NFI-binding sites with BAT FAIRE peaks is higher than that of NFI-binding sites with eWAT FAIRE peaks ( Supplementary Fig. 7a,b) . In support of this, a transcriptome analysis independently suggested that NFIA would be a positive regulator of brown adipocyte differentiation 40 . Interestingly, it is reported that NFIC negatively regulates adipocyte differentiation 41 . Future studies will be needed to understand the mechanisms underlying differential regulation of brown adipocyte differentiation by different isoforms of NFI family.
Developing a therapy for obesity through activating BAT is highly anticipated. Recently, an epigenome-wide association study showed that DNA methylation of a CpG site at the intron of NFIA in human adipose tissue shows a positive and significant association (P = 4.0 × 10 −20 ) with obesity 42 , suggesting that downregulation of NFIA may contribute to pathophysiology of obesity in humans. Identifying an upstream regulator of NFIA may open a door for BATtargeted anti-obesity therapy.
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